middle.news
NIH backs wider patient access to Neurizon’s NUZ-001 ALS therapy
9:55am on Wednesday 9th of September, 2026 AEST
•
Biotechnology
Read Story
NIH backs wider patient access to Neurizon’s NUZ-001 ALS therapy
9:55am on Wednesday 9th of September, 2026 AEST
Key Points
NIH-funded program targeting up to 200 trial-ineligible ALS patients
Access to NUZ-001 planned for up to 96 weeks
Grant covers drug supply, manufacturing and specified regulatory costs
Enrolment targeted to begin by Q1 CY2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE